Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know

The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti–platelet factor 4 ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Arepally, Gowthami M., Ortel, Thomas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Blood Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172307/
https://www.ncbi.nlm.nih.gov/pubmed/34323940
http://dx.doi.org/10.1182/blood.2021012152
Descripción
Sumario:The development of vaccines to fight COVID-19 has been a remarkable medical achievement. However, this global immunization effort has been complicated by a rare vaccine-related outcome characterized by thrombocytopenia and thrombosis in association with platelet-activating anti–platelet factor 4 antibodies. In this Spotlight, we will discuss the recently described complication of vaccine-induced immune thrombotic thrombocytopenia (VITT) occurring in response to certain COVID-19 vaccines. Although information about this clinical condition is rapidly evolving, we will summarize our current understanding of VITT.

Ejemplares similares